The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...

AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

Drugs are man-made miracles. They enhance our health, cure diseases, and extend our lives. However, drug development is not easy. It is a remarkably long, expensive, and complex process. On average, ...

Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...

Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue to rise. Meanwhile, ...

In today's fast-paced and ever-evolving landscape of clinical trials, the ability to efficiently analyze and visualize data has become paramount. The vast amounts of data generated from these trials ...

Boundless Bio has announced it will not advance BBI-825 into the second part of the STARMAP clinical trial due to challenges related to emerging clinical data and the competitive landscape for ...